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Sir,
Duran et al (10 October 2006) reported the results of a phase II
trial of temsirolimus in 37 patients with advanced neuroendocrine
carcinomas (NEC). The authors cite an intent-to-treat response
rate of 5.6% (two out of 36 patients who received temsiroliums
achieved a partial response by RECIST criteria), and conclude
therefore that ‘temsirolimus appears to have little activity and does
not warrant further single-agent evaluation in advanced NEC’. Yet,
Duran et al found that tumour control (partial response plus stable
disease), measured as the percent tumour change from baseline,
was achieved in 23 out of the 36 patients (63.9%) on temsirolimus.
When it is considered that all patients in this trial had to have
documented, progressive disease within 6 months of the study
entry, the significant percentage of patients experiencing disease
stabilisation on temsirolimus and the 1-year progression-free rate
of 40.1% suggest drug activity beyond the natural course of the
disease. Temsirolimus also compares favourably with other agents
previously studied in NEC (Oberg, 2002). As a comparison, Faiss
et al (2003) prospectively studied the use of interferon-alpha and
the somatostatin analogue lanreotide in treatment-naı ¨ve NEC
patients and found tumour control rates of 32% (lanreotide),
30% (interferon-alpha), and 25% (combination) at 1 year. Another
study of 15 patients with metastatic NEC refractory to lanreotide
examined the use of slow-release octreotide, and a partial response
was seen in 7% of patients, stable disease in 40%, and progressive
disease in 53% (Ricci et al, 2000). Duran et al also cite other recent
reports of the use of sunitinib and, separately, gefitinib in NEC and
acknowledge that the response rate and median time to progres-
sion with temsirolimus ‘compares favourably with other targeted
therapies tested in this tumour population’.
This trial exemplifies the difficulty of interpreting the results of
single-arm trials using the RECIST criteria (Michaelis and Ratain,
2006). This is especially true for noncytotoxic agents being studied
in indolent diseases for which one would expect a high rate of
stable disease in the absence of treatment. In fact, the response rate
for temsirolimus in NEC compares favourably to that observed
with sorafenib in advanced renal cell cancer, where the RECIST
response rate is less than 5% (Ratain et al, 2006). Furthermore, if
one compares the figures demonstrating ‘tumour size change from
baseline’ for sorafenib in renal cell cancer to that of temsirolimus
in NEC, the response distributions are nearly identical. However,
the use of a randomised discontinuation design for the phase II
trial of sorafenib demonstrated convincing evidence of activity
and its subsequent widespread approval for the treatment of this
disease. Rather than abandoning further evaluation of temsirolimus
as a single-agent therapy for NEC, one should abandon the
concept of single-arm studies of novel agents in neuroendocrine
carcinomas.
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